Insight Molecular Diagnostics Inc. Revenue Disclosure
7. Disaggregation of Revenues and Concentration Risk
The following table presents the percentage of consolidated revenues attributable to products or services classes that represent greater than ten percent of consolidated revenues:
| Year Ended | ||||||||
| December 31, | ||||||||
| 2022 | 2021 | |||||||
| Pharma Services | 17 | % | 19 | % | ||||
| Licensing | - | % | 10 | % | ||||
| Discontinued operations | 83 | % | 71 | % | ||||
| Total | 100 | % | 100 | % | ||||
The following table presents the percentage of consolidated revenues received from unaffiliated customers that individually represent greater than ten percent of consolidated revenues:
| Year Ended | ||||||||
| December 31, | ||||||||
| 2022 | 2021 | |||||||
| Pharma services - Company A | 43 | % | * | |||||
| Pharma services - Company B | 14 | % | * | |||||
| Pharma services - Company C | 11 | % | * | |||||
| Pharma services Other | 31 | % | 66 | % | ||||
| Licensing - Company A | * | 34 | % | |||||
| * | Less than 10% |
The following table presents the percentage of consolidated revenues attributable to geographical locations:
| Year Ended | ||||||||
| December 31, | ||||||||
| 2022 | 2021 | |||||||
| United States – Pharma Services | 13 | % | 13 | % | ||||
| Outside of the United States – Pharma Services | 4 | % | 6 | % | ||||
| Outside of the United States – Licensing | % | 10 | % | |||||
| Discontinued operations – Outside of the United States - Licensing | 18 | % | 40 | % | ||||
| Discontinued operations – United States - DetermaRx | 65 | % | 31 | % | ||||
| Total | 100 | % | 100 | % | ||||
The total consolidated accounts receivables, from third-party payers and other customers outstanding as of December 31, 2022 from continuing operations are mainly related to Pharma Services.
ONCOCYTE CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2022 | Apr 12, 2023 | Showing above |
| 2021 | Mar 11, 2022 | |
| 2020 | Mar 19, 2021 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.